Cheng Xin, Lou Kecheng, Ding Liang, Zou Xiaofeng, Huang Ruohui, Xu Gang, Zou Junrong, Zhang Guoxi
First Clinical College, Gannan Medical University, Ganzhou, China.
Department of Urology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Front Oncol. 2022 Jul 15;12:925278. doi: 10.3389/fonc.2022.925278. eCollection 2022.
Bladder cancer (BC) is one of the world's most frequent cancers. Surgery coupled with adjuvant platinum-based chemotherapy is the current standard of therapy for BC. However, a high proportion of patients progressed to chemotherapy-resistant or even neoplasm recurrence. Hence, identifying novel treatment targets is critical for clinical treatment. Current studies indicated that the Hippo-YAP pathway plays a crucial in regulating the survival of cancer stem cells (CSCs), which is related to the progression and reoccurrence of a variety of cancers. In this review, we summarize the evidence that Hippo-YAP mediates the occurrence, progression and chemotherapy resistance in BC, as well as the role of the Hippo-YAP pathway in regulating bladder cancer stem-like cells (BCSCs). Finally, the clinical potential of Hippo-YAP in the treatment of BC was prospected.
膀胱癌（BC）是全球最常见的癌症之一。手术联合铂类辅助化疗是目前BC的标准治疗方案。然而，很大一部分患者会进展为化疗耐药甚至肿瘤复发。因此，确定新的治疗靶点对临床治疗至关重要。目前的研究表明，Hippo-YAP信号通路在调节癌症干细胞（CSC）的存活中起关键作用，这与多种癌症的进展和复发有关。在这篇综述中，我们总结了Hippo-YAP介导BC发生、进展和化疗耐药的证据，以及Hippo-YAP信号通路在调节膀胱癌干细胞样细胞（BCSC）中的作用。最后，展望了Hippo-YAP在BC治疗中的临床潜力。
